A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

• Status: Recruiting
• Trial end date: 2025-12-31

Summary

This is a open-label，multicenter, randomised, three-arm, phase II efficacy and safety study of ibrutinib in combination with MRE(methotrexate,rituximab,etoposide)-chemotherapy versus lenalidomide in combination with MRE-chemotherapy given to adult patients who have recurrent/refractory primary central nervous system lymphoma (PCNSL)

• Phase: Phase 2

Details

• Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Collaborators: Cancer Hospital of Guangxi Medical University; Fujian Medical University Union Hospital; Ningbo Medical Center Lihuili Hospital; RenJi Hospital; Ruijin Hospital; Shandong Provincial Hospital; Shanghai Tong Ren Hospital; Sir Run Run Shaw Hospital; Taizhou Hospital of Zhejiang Province; The First Affiliated Hospital of Nanchang University; Yinzhou Hospital Affiliated to Medical School of Ningbo University; Zhejiang University
• Treatments: Etoposide; Etoposide phosphate; Lenalidomide; Methotrexate; Rituximab